Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I ...

A year of daily subcutaneous vosoritide was associated with a 0.6-inch (1.5-cm) greater increase in height than placebo in children with achondroplasia, the most common form of human dwarfism ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

PALO ALTO, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, and QED ...

Achondroplasia is a genetic bone disorder affecting about one in every 25,000 infants. It is caused by a mutation in the FGFR3 gene that impairs the growth of bones in the limbs, ...

About Achondroplasia Achondroplasia is the most common form of dwarfism, affecting approximately 250,000 people worldwide. Individuals living with achondroplasia may experience severe skeletal ...

BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study - 50% Increase in mean annualized growth velocity in 15 ug/kg/daily dose group - BMN 111 was well ...

Barcelona star Lamine Yamal has been in the crosshairs of the Spanish media this week, following his 18th birthday party on ...

Barcelona forward Lamine Yamal is back in training with the rest of his teammates this week as the Catalan side begin ...

Barcelona’s star forward Lamine Yamal bluntly brushed off the controversy surrounding the allegedly illegal hiring of people ...

Performers defend their presence at the footballer’s 18th birthday and reject a statement made on their behalf by a ...